Table 4

Results of sub-analysis by treatment or DGR for the VEGF-A rs833061 polymorphism and treatment response of nAMD

		FEM or REM*		Heterogeneity
No. of cohorts	Genetic model	OR (95% CI)	p (Q)	p (Q)	I² (%)
Sub-analysis by treatment
RBZ	C vs T	1.365 (1.039 to 1.792)	0.025	0.684	0.0
	CC vs TT	2.222 (1.252 to 3.944)	0.001	0.992	0.0
	CT vs TT	3.327 (1.709 to 5.590)	0.000	0.878	0.0
	CC vs CT+TT	3.091 (1.025 to 3.661)	0.000	0.965	0.0
	CC+CT vs TT	1.071 (0.731 to 1.568)	0.726	0.678	0.0
RBZ or BVZ	C vs T	0.778 (0.386 to 1.566)	0.481	n.a	n.a
	CC vs TT	0.559 (0.121 to 2.587)	0.457	n.a	n.a
	CT vs TT	0.690 (0.171 to 2.782)	0.602	n.a	n.a
	CC vs CT+TT	0.644 (1.369 to 8.145)	0.519	n.a	n.a
	CC+CT vs TT	0.739 (0.249 to 2.190)	0.585	n.a	n.a
Sub-analysis by DGR
VA	C vs T	1.307 (0.963 to 1.773)	0.085	0.534	0.0
	CC vs TT	2.827 (1.355 to 5.900)	0.006	0.923	0.0
	CT vs TT	3.631 (1.777 to 7.418)	0.000	0.841	0.0
	CC vs CT+TT	3.226 (1.630 to 6.385)	0.001	0.903	0.0
	CC+CT vs TT	0.997 (0.654 to 1.518)	0.988	0.712	0.0
OCT	C vs T	1.181 (0.751 to 1.857)	0.472	0.122	58.2
	CC vs TT	1.463 (0.571 to 3.746)	0.428	0.104	62.1
	CT vs TT	1.446 (0.607 to 3.441)	0.405	0.168	47.4
	CC vs CT+TT	1.458 (0.647 to 3.285)	0.363	0.114	59.9
	CC+CT vs TT	1.125 (0.558 to 2.269)	0.742	0.327	0.0

If the p value for Q-statistic was >0.10 or the I2 value was ≥50%, a REM was used, otherwise a FEM was adopted.
BVZ, bevacizumab; DGR, definition of a good response; FEM, fixed-effects model; nAMD, neovascular age-related macular degeneration; OCT, optical coherence tomography; RBZ, ranibizumab; REM, random-effects model; VA, visual acuity; VEGF-A, vascular endothelial growth factor A.